Trials / No Longer Available
No Longer AvailableNCT04173013
Expanded Access Program Using Uromune for Patients With Recurrent Urinary Tract Infections (rUTI)
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Impatients N.V. trading as myTomorrows · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
An Expanded Access Program for UROMUNE® for patients suffering from recurrent/chronic urinary tract infections of diverse etiology. This is for individuals for whom antibiotic therapy has failed, but of consideration in all cases, taking into account antibiotic-induced adverse reactions and increasing antibiotic resistance.
Detailed description
UROMUNE® is a mucosal immunotherapy indicated for the prevention of urinary tract infections caused by different pathogens. It works by stimulating the immune system, thus increasing the resistance against recurrent infections. The active substances are 4 inactivated and selected bacterial strains: * Klebsiella pneumoniae 25% * Escherichia coli 25% * Enterococcus faecalis 25% * Proteus vulgaris 25%
Conditions
- Urinary Tract Infections
- Chronic Urinary Tract Infection
- Recurrent Urinary Tract Infection
- Urinary Tract Infection Bacterial
- Bladder Infection
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Uromune | 2 sprays of solution once daily for a total of 3 months. |
Timeline
- First posted
- 2019-11-21
- Last updated
- 2023-09-29
Locations
15 sites across 15 countries: Belgium, Czechia, Denmark, Finland, France, Germany, Luxembourg, Netherlands, Norway, Romania, Serbia, Slovakia, Slovenia, Sweden, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT04173013. Inclusion in this directory is not an endorsement.